ReviewPharmacotherapy2017
Pharmacotherapeutic Considerations for Individuals with Down Syndrome.
Review in Pharmacotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- The effect of exercise on improving cognitive function in people with Down's syndrome: a systematic review and meta-analysis.European journal of pediatrics · 2025Pooled it
- The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023Trial
- Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.Current opinion in rheumatology · 2026Review
- Anticholinergic Burden in Individuals with Down Syndrome: An Examination of Risk and Clinical Implications.Journal of personalized medicine · 2026Article
- From classroom to the counter: exploring knowledge, attitudes, and practices toward Down syndrome among pharmacy students and pharmacists.BMC medical education · 2026Article
- Assessment of knowledge, attitudes, pharmacotherapy counseling, and patient education about Down syndrome among community pharmacists: a cross-sectional study.Frontiers in public health · 2026Article
- Anticholinergics, executive function, and cognitive/behavioral changes in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Article
- Current evidence on drug therapy for dementia in people with Down syndrome: an overview of systematic reviews.Dementia & neuropsychologia · 2025Review
- Analysis of the intracellular traffic of IgG in the context of Down syndrome (trisomy 21).Scientific reports · 2021Article
- Emergent high fatality lung disease in systemic juvenile arthritis.Annals of the rheumatic diseases · 2019Article
- Dementia in Down syndrome: unique insights for Alzheimer disease research.Nature reviews. Neurology · 2019Review
- Aging With Down Syndrome: The Dual Diagnosis: Alzheimer's Disease and Down Syndrome.American journal of Alzheimer's disease and other dementias · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Down syndrome (DS; trisomy 21) is the most common survivable disorder due to aneuploidy. Individuals with DS may experience multiple comorbid health problems including congenital heart defects, endocrine abnormalities, skin and dental problems, seizure disorders, leukemia, dementia, and obesity. These associated conditions may necessitate pharmacotherapeutic management with various drugs. The complex pathobiology of DS may alter drug disposition and drug response in some individuals. For example, reports have documented increased rates of adverse drug reactions in patients with DS treated for leukemia and dementia. Intellectual disability resulting from DS may impact adherence to medication regimens. In this review, we highlight literature focused on pharmacotherapy for individuals with DS. We discuss reports of altered drug disposition or response in patients with DS and explore social factors that may impact medication adherence in the DS setting. Enhanced monitoring during drug therapy in individuals with DS is justified based on reports of altered drug disposition, drug response, and other characteristics present in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.